ArticleJournal of the American Heart Association2025
Evolving Trends and Drug Class Dynamics in Drug-Induced Myocarditis: A 2-Decade Comparative Analysis of Pharmacovigilance Data.
Article in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDrug-induced myocarditis has emerged as an increasingly significant concern with both established and novel medications. This study aimed to identify temporal trends and high-risk populations in drug-induced myocarditis through cross-regulatory pharmacovigilance analysis.
methodsData from the US Food and Drug Administration Adverse Event Reporting System and the Japanese Adverse Drug Event Report databases were analyzed from 2004 to 2023. Drugs associated with myocarditis were identified and classified by therapeutic class, with trends evaluated using linear regression, stratified by age and sex.
resultsDrug-induced myocarditis was reported in 9983 cases in the US Food and Drug Administration Adverse Event Reporting System (increasing from 114 to 1819) and 3718 cases in the Japanese Adverse Drug Event Report database (rising from 18 to 655) from 2004 to 2023. Monoclonal antibodies and antipsychotics were the fastest-growing risk categories, a trend led by monoclonal antibodies in the US Food and Drug Administration Adverse Event Reporting System (+26.82 cases/year) and corroborated in the Japanese Adverse Drug Event Report database (+13.88 cases per year). Clozapine was the most frequently reported single drug in the US Food and Drug Administration Adverse Event Reporting System (12.79% of all cases, +6.96 cases per year). These trends showed consistent patterns across population subgroups; age-stratified analysis revealed that the increase in monoclonal antibodies was concentrated in the older group, whereas the trend for antipsychotics was most prominent in adults. Gender-specific analysis showed that trends for monoclonal antibodies and antipsychotics were more pronounced in men, whereas chemotherapy agents increased more in women.
conclusionsIntegrated analysis of multinational pharmacovigilance data enhances real-time risk detection and underscores the need for precision surveillance strategies targeting high-risk therapies and vulnerable populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.